Cargando…

Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma

BACKGROUND: A universally acknowledged cancer staging system considering all aspects of the T‐, N‐, and M‐classifications for middle ear squamous cell carcinoma (MESCC) remains absent, limiting the clinical management of MESCC patients. MATERIALS AND METHODS: A total of 214 MESCC patients were extra...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Ke, Pang, Wendu, Qiu, Jianqing, Li, Junhong, Cheng, Danni, Rao, Yufang, Dong, Yijun, Mao, Minzi, Liu, Qiurui, Mu, Xiaosong, Zhang, Wei, Xu, Wei, Ren, Jianjun, Zhao, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607269/
https://www.ncbi.nlm.nih.gov/pubmed/34559476
http://dx.doi.org/10.1002/cam4.4306
_version_ 1784602531052126208
author Qiu, Ke
Pang, Wendu
Qiu, Jianqing
Li, Junhong
Cheng, Danni
Rao, Yufang
Dong, Yijun
Mao, Minzi
Liu, Qiurui
Mu, Xiaosong
Zhang, Wei
Xu, Wei
Ren, Jianjun
Zhao, Yu
author_facet Qiu, Ke
Pang, Wendu
Qiu, Jianqing
Li, Junhong
Cheng, Danni
Rao, Yufang
Dong, Yijun
Mao, Minzi
Liu, Qiurui
Mu, Xiaosong
Zhang, Wei
Xu, Wei
Ren, Jianjun
Zhao, Yu
author_sort Qiu, Ke
collection PubMed
description BACKGROUND: A universally acknowledged cancer staging system considering all aspects of the T‐, N‐, and M‐classifications for middle ear squamous cell carcinoma (MESCC) remains absent, limiting the clinical management of MESCC patients. MATERIALS AND METHODS: A total of 214 MESCC patients were extracted from the SEER (the Surveillance, Epidemiology, and End Results) database between 1973 and 2016. The relationships between patient’s characteristics and prognoses were analyzed by Kaplan–Meier and Cox proportional hazards regression models. Novel staging schemes for MESCC were designed by adjusted hazard ratio (AHR) modeling method according to the combinations of Stell’s T‐classification and the eighth AJCC N‐ and M‐classifications, of which performances were evaluated based on five criteria: hazard consistency, hazard discrimination, explained variation, likelihood difference, and balance. RESULTS: T‐classification was the most significant prognostic factor for MESCC patients in multivariable analysis (p = 0.021). The N‐ and M‐classifications also had obvious prognostic effect but were not statistically significant by multivariate analysis due to the limited metastasis events. Three novel staging schemes (AHR‐Ⅰ–Ⅲ models, different combination of T‐ and N‐classifications) and ST (solely derived from Stell’s T‐classification) were developed, among which the AHR‐Ⅰ staging scheme performed best. CONCLUSIONS: Tumor extension, quantified by Stell’s T‐classification, is the most significant prognostic factor for MESCC patients. However, our AHR‐Ⅰ staging scheme, a comprehensive staging scheme that integrating T‐, N‐, and M‐classifications, might be an optimal option for clinical practitioners to predict MESCC patients’ prognosis and make proper clinical decisions.
format Online
Article
Text
id pubmed-8607269
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86072692021-11-29 Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma Qiu, Ke Pang, Wendu Qiu, Jianqing Li, Junhong Cheng, Danni Rao, Yufang Dong, Yijun Mao, Minzi Liu, Qiurui Mu, Xiaosong Zhang, Wei Xu, Wei Ren, Jianjun Zhao, Yu Cancer Med Clinical Cancer Research BACKGROUND: A universally acknowledged cancer staging system considering all aspects of the T‐, N‐, and M‐classifications for middle ear squamous cell carcinoma (MESCC) remains absent, limiting the clinical management of MESCC patients. MATERIALS AND METHODS: A total of 214 MESCC patients were extracted from the SEER (the Surveillance, Epidemiology, and End Results) database between 1973 and 2016. The relationships between patient’s characteristics and prognoses were analyzed by Kaplan–Meier and Cox proportional hazards regression models. Novel staging schemes for MESCC were designed by adjusted hazard ratio (AHR) modeling method according to the combinations of Stell’s T‐classification and the eighth AJCC N‐ and M‐classifications, of which performances were evaluated based on five criteria: hazard consistency, hazard discrimination, explained variation, likelihood difference, and balance. RESULTS: T‐classification was the most significant prognostic factor for MESCC patients in multivariable analysis (p = 0.021). The N‐ and M‐classifications also had obvious prognostic effect but were not statistically significant by multivariate analysis due to the limited metastasis events. Three novel staging schemes (AHR‐Ⅰ–Ⅲ models, different combination of T‐ and N‐classifications) and ST (solely derived from Stell’s T‐classification) were developed, among which the AHR‐Ⅰ staging scheme performed best. CONCLUSIONS: Tumor extension, quantified by Stell’s T‐classification, is the most significant prognostic factor for MESCC patients. However, our AHR‐Ⅰ staging scheme, a comprehensive staging scheme that integrating T‐, N‐, and M‐classifications, might be an optimal option for clinical practitioners to predict MESCC patients’ prognosis and make proper clinical decisions. John Wiley and Sons Inc. 2021-09-24 /pmc/articles/PMC8607269/ /pubmed/34559476 http://dx.doi.org/10.1002/cam4.4306 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Qiu, Ke
Pang, Wendu
Qiu, Jianqing
Li, Junhong
Cheng, Danni
Rao, Yufang
Dong, Yijun
Mao, Minzi
Liu, Qiurui
Mu, Xiaosong
Zhang, Wei
Xu, Wei
Ren, Jianjun
Zhao, Yu
Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
title Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
title_full Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
title_fullStr Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
title_full_unstemmed Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
title_short Evaluating the prognostic contributions of TNM classifications and building novel staging schemes for middle ear squamous cell carcinoma
title_sort evaluating the prognostic contributions of tnm classifications and building novel staging schemes for middle ear squamous cell carcinoma
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607269/
https://www.ncbi.nlm.nih.gov/pubmed/34559476
http://dx.doi.org/10.1002/cam4.4306
work_keys_str_mv AT qiuke evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT pangwendu evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT qiujianqing evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT lijunhong evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT chengdanni evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT raoyufang evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT dongyijun evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT maominzi evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT liuqiurui evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT muxiaosong evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT zhangwei evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT xuwei evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT renjianjun evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma
AT zhaoyu evaluatingtheprognosticcontributionsoftnmclassificationsandbuildingnovelstagingschemesformiddleearsquamouscellcarcinoma